DOLE-EUROPE-IMPORT
29.5.2014 18:01:10 CEST | Business Wire | Pressemeddelelse
On May 26th fresh produce provider Dole Europe Import BVBA signed the Sustainability Initiative Fruits and Vegetables (SIFAV) covenant at Dole Europe's headquarters in Hamburg. The Sustainability Initiative Fruit and Vegetables, powered by IDH, aims to make global imports from developing countries 100% sustainable by 2020. "The SIFAV covenant is an important milestone and commitment for Dole Europe Import reflecting the continuous improvement in Dole's Corporate Responsibility and Sustainability policies as implemented in our operations," says Johan Linden, president of Dole Europe.
By signing the SIFAV Covenant, large retailers and brands commit to have 100% of their fruit produced in a sustainable manner by 2020. ICCO, Solidaridad, and Frugi Venta support the covenant with their sector expertise. The program is coordinated by IDH, The Sustainable Trade Initiative.
Joost van Oorthuizen, General Director, IDH: "We are very pleased to be working with Dole, a leading fresh fruits provider that has Corporate Social Responsibility so high on its agenda. We believe and hope that this incentivizes producers to follow in Dole's footsteps and become more sustainable."
About IDH
IDH, The Sustainable Trade Initiative accelerates and up-scales sustainable trade by building impact oriented coalitions of front running companies, civil society organizations, governments and other stakeholders. By convening public & private interests, strengths, and knowledge, the 18 IDH programs sustainably transform commodity markets to create large scale improvements in the livelihoods of hundreds of thousands of small scale farmers, reduce negative environmental impact, and support local value creation in developing countries - making sustainable production and consumption the norm. More information: idhsustainabletrade.com & SIFAV.com.
About Dole Europe Import
Dole Europe Import BVBA is a European subsidiary of Dole Food Company, Inc., one of the world’s largest suppliers of fresh fruit and vegetables. Dole Europe Import imports a wide range of fresh fruit and vegetables from both Dole’s own farms and independent growers from all over the world. More information: dole.eu and dolecrs.com.
Note to editors
For more information and interviews please contact Iris Tzur, Communication Manager at IDH: +31 (0)30-230 7872/ +31 (0)6-21147951, tzur@idhsustainabletrade.com or Xavier Roussel, Marketing and Communication Director at Dole Europe +49(0)40.32.90.60 xavier.roussel@dole.com
Contact:
IDH
Iris Tzur, Communication Manager, +31 (0)30-230 7872 / +31
(0)6-21147951
tzur@idhsustainabletrade.com
or
Dole
Europe
Xavier Roussel, Marketing and Communication Director,
+49(0)40.32.90.60
xavier.roussel@dole.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum